Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Siamoglou, Stavroula; Boers, Ruben; Koromina, Maria; Boers, Joachim; Tsironi, Anna; Chatzilygeroudi, Theodora; Lazaris, Vasileios; Verigou, Evgenia; Kourakli, Alexandra; van IJcken, Wilfred F. J.; Gribnau, Joost; Symeonidis, Argiris; Patrinos, George P.

doi:10.1186/s40246-023-00483-7

Human Genomics

Table 4 Differentially methylated regions (DMRs) with fold change values above 3.5 after comparing individuals with RAEBI MDS subtype against individuals with MDS but without an excess of blasts

From: Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Chromosome	Start	End	Fold Change	Genomic loci description	Genomic annotation
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA1
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA1
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA2
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA2
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA3
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA3
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGB1
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGB1
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA4
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA4
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGB2
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGB2
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA5
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA5
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGB3
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGB3
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA6
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA6
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA7
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA7
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGB4
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGB4
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA8
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA8
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGB5
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGB5
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGA9
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGA9
chr5	141,491,020	141,491,136	5.70	postTSS1KB-TES	PCDHGB6
chr5	141,491,405	141,491,458	4.96	postTSS1KB-TES	PCDHGB6
chr15	26,891,159	26,892,850	4.89	CpG-island	CpG14631
chr15	26,891,159	26,892,850	4.89	postTSS1KB-TES	GABRB3
chr15	26,891,159	26,892,850	4.89	postTSS1KB-TES	GABRA5
chr15	26,773,368	26,773,480	3.74	CpG-island	CpG14624
chr15	26,773,368	26,773,480	3.74	postTSS1KB-TES	GABRB3

Chromosome loci of the DMRs, fold change and genomic annotation with regard to the identified DMRs. TSS Transcription Start Site, TES Transcription End Site; postTSS1KB-TES, indicates the region starting at 1 Kb after the TSS until the TES thus corresponding to the gene body without promoter region

Back to article page

ISSN: 1479-7364

Contact us

General enquiries: journalsubmissions@springernature.com